Bridgefront Capital, LLC Biomarin Pharmaceutical Inc Transaction History
Bridgefront Capital, LLC
- $249 Million
- Q3 2024
A detailed history of Bridgefront Capital, LLC transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Bridgefront Capital, LLC holds 8,235 shares of BMRN stock, worth $545,733. This represents 0.23% of its overall portfolio holdings.
Number of Shares
8,235Holding current value
$545,733% of portfolio
0.23%Shares
6 transactions
Others Institutions Holding BMRN
# of Institutions
637Shares Held
177MCall Options Held
2.01MPut Options Held
1.28M-
Black Rock Inc. New York, NY22.7MShares$1.51 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA19.3MShares$1.28 Billion0.02% of portfolio
-
Primecap Management CO Pasadena, CA18.9MShares$1.25 Billion0.99% of portfolio
-
Dodge & Cox San Francisco, CA13.9MShares$921 Million0.59% of portfolio
-
Capital Research Global Investors Los Angeles, CA10.5MShares$696 Million0.16% of portfolio
About BIOMARIN PHARMACEUTICAL INC
- Ticker BMRN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,824,000
- Market Cap $12.3B
- Description
- BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...